TABLE 1.
Baseline demographic and clinical characteristics of participants
| Computer Group (n=39) | Control Group (n=39) | |
|---|---|---|
| Age (years), median (range) | 54 (27-80) | 59 (24-75) |
| Sex (Male / Female) | 29 / 10 | 26 / 13 |
| Total bodyweight (kg)a | 83.9 (21.5) | 79.1 (16.6) |
| Height (cm) | 176 (9) | 174 (10) |
| Predicted fat-free mass (kg)a | 58.7 (11) | 55.7 (11) |
| Hematocrit (%)a | 31 (4) | 31 (4) |
| CYP3A5 genotype (*3/*3, *1/*3, *1/*1) | 31 / 8 / 0 | 31 / 8 / 0 |
| CYP3A4 genotype (*1/*1, *1/*22, *22/*22) | 35 / 4 / 0 | 35 / 4 / 0 |
| Prior transplantations (≥1) | 2 | 2 |
| Delayed graft functionb | 6 | 9 |
| Panel reactive antibodies (≥20%) | 0 | 2 |
| Donor specific antibodies | 2 | 3 |
| Donor age (years), median (range) | 53 (5-77) | 60 (3-78) |
| Donor (Living / Deceased) | 15 / 24 | 7 / 32 |
| ABO mismatches | 5 | 0 |
| HLA mismatches | ||
| A (0 / 1 / 2) | 8 / 20 / 11 | 15 / 18 / 6 |
| B (0 / 1 / 2) | 4 / 21 / 14 | 7 / 23 / 9 |
| DR (0 / 1 / 2) | 12 / 18 / 9 | 13 / 24 / 2 |
Values are shown as numbers or mean (standard deviation) unless stated otherwise
CYP3A5, Cytochrome P450 3A5; CYP3A4, Cytchrome P450 3A4; HLA, human leukocyte antigen
a
One week post-transplant
b
Defined by the use of dialysis during the first week post-transplant (47)